Oxford Immunotec Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., 2017-02-14 22:05 CET (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC(Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release fourth quarter and full year 2016 financial results after the close of the market on Tuesday, February 28, 2017. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 5:00 p.m. Eastern Time the same day. The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 59419141, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website atwww.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT®.TBtest, which is used to test for tuberculosis infection. The T-SPOT.TBtest has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. The T-SPOT.CMVtest and the T-SPOT.PRTtest are part of the Company's third product line focused on the transplantation market. In addition to these three product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found atwww.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0501
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Concurrent Computer Corporation13.12.2017 22:49 | pressemeddelelse
Concurrent Stockholders Approve Proposal to Sell Content Delivery & Storage Business to Vecima Networks
Datalliance13.12.2017 22:16 | pressemeddelelse
TrueCommerce Announces Integration with AccountMate Business Management Solution
SMU Cox School of Business13.12.2017 21:47 | pressemeddelelse
STEM Designation Granted for SMU Cox Master of Science in Finance
Hitachi Vantara13.12.2017 15:01 | pressemeddelelse
Hitachi Vantara Continues To Bolster Its Global Leadership Team With New Executive Appointments
Tyco Retail Solutions13.12.2017 12:12 | pressemeddelelse
DTLR Selects ShopperTrak Traffic Insights to Optimize Store Performance
Percona13.12.2017 09:04 | pressemeddelelse
Percona Collaborates with AWS on Database Delivery Service
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum